Jillian Marconi

Jillian Marconi serves as a key procurement professional within the National Institute of Allergy and Infectious Diseases (NIAID), supporting the agency’s mission to accelerate biomedical research responses to infectious, immunologic, and allergic threats. She manages complex acquisitions for high-containment laboratory infrastructure, diagnostic tools, and medical countermeasures, ensuring alignment with federal biosafety standards and public health preparedness goals. Her portfolio emphasizes scientific instrumentation, biotechnology R&D services, and analytical laboratory capabilities critical to advancing NIAID’s research pipeline and emergency response readiness. Marconi maintains strategic relationships with specialized vendors including Quality Biological, Inc., a leading provider of biological reference materials, and Genomic Labs Ltd., a key supplier of advanced genomic analysis services. Her contracting approach prioritizes technical precision and regulatory compliance, often engaging niche manufacturers and testing laboratories with proven expertise in biosafety level 3 and 4 environments. These partnerships reflect a preference for vendors with deep domain knowledge in infectious disease research, biospecimen handling, and high-containment facility support. Her procurement strategy reflects a strong emphasis on broad market access, with 80% of acquisitions conducted under full and open competition and 20% reserved for total small business set-asides under FAR 19.5. While she does not prioritize specific socioeconomic categories like 8(a) or HUBZone, her consistent use of small business set-asides demonstrates a deliberate commitment to fostering innovation from emerging scientific contractors and specialized service providers. Marconi’s primary NAICS focus includes analytical laboratory instrument manufacturing (334516), testing laboratory services (541380), and biotechnology R&D (541714), reflecting her specialization in procuring precision diagnostic equipment, biosafety-certified testing infrastructure, and cutting-edge biotech research services. Her expertise lies in acquiring complex, regulated scientific systems critical to pathogen characterization, vaccine development, and high-containment research operations.